Exagen
XGN

$2.01

5.42%

Market Cap: 34.9M

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 179

Healthcare Medical Laboratories

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 0

3% more funds holding

Funds holding: 30 [Q4 2023] → 31 (+1) [Q1 2024]

3.25% less ownership

Funds ownership: 39.24% [Q4 2023] → 35.99% (-3.25%) [Q1 2024]

26% less capital invested

Capital invested by funds: $13.3M [Q4 2023] → $9.87M (-$3.45M) [Q1 2024]

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

57% less call options, than puts

Call options by funds: $3K | Put options by funds: $7K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$7

248%

upside

Avg. target

$7

248%

upside

High target

$7

248%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald

Ross Osborn

248%upside

$7

Overweight

Maintained

14 May 2024

See Analyst Rankings

Financial journalist opinion

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Zacks Investment Research

Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors' minds. This is because investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio.

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Zacks Investment Research

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

Exagen, Inc. (NASDAQ:XGN ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Operator Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago.

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024.

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Exagen to Announce First Quarter 2024 Results on May 13, 2024

CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Exagen Inc. Announces Changes to the Board of Directors

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.

Exagen Inc. Announces Changes to the Board of Directors

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

See News Rankings